Bioavailability and efficacy of antisense Morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats

Journal of Pharmaceutical Sciences

Volumn 91, Issue 4, 2002, Pages 1009-1018

  Arora, Vikram ^a   Knapp, Derek C ^a   Reddy, Muralimohan T ^a   Weller, Dwight D ^a   Iversen, Patrick L ^a  

^a AVI BIOPHARMA INC   (United States)

Author keywords

Antisense; CYP3A2; Myc; Oral bioavailability; Phosphorodiamidate morpholino

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AVI 4126; CYCLIN D1; CYCLINE; CYTOCHROME P450 3A2; ERYTHROMYCIN; MORPHOLINE DERIVATIVE; MYC PROTEIN; OLIGOMER; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG STABILITY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; IMMUNOBLOTTING; LIVER METABOLISM; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; RAT; SEQUENCE ANALYSIS;

EID: 0036279927     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10088     Document Type: Article

References (27)

1. Morpholino antisense oligomers: The case for an RNase H-independent structural type
2. Antisense properties of morpholino oligomers
3. Morpholino anti-sense oligomers: Design, preparation, and properties
4. Evaluation of antisense mechanisms of action
5. Antisense morpholino oligonucleotide analog induces missplicing of c-myc mRNA
6. Antiproliferative effects of steric blocking phosphorodiamidate morpholine antisense agents directed against c-myc
7. c-Myc antisense limits rat liver regeneration and indicates role for c-myc in regulating cytochrome P-450 3A activity
8. Antisense oligonucleotides targeted to the p53 gene modulate liver regeneration in vivo
9. In vivo evaluation of a morpholino antisense oligomer directed against tumor necrosis factor-α
10. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation
11. Liver regeneration
12. Alterations in mRNA stability during rat liver regeneration
13. Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo
14. Restoration of liver following partial surgical removal
15. The molecular biology cytochrome P450s
16. Pkcalc: A basic interactive computer program for statistical and pharmacokinetic analysis of data
17. Use of proliferating cell nuclear antigen as a marker of liver regeneration after partial hepatectomy in rats
18. Comparison of proliferating cell nuclear antigen to tritiated thymidine as a marker of proliferting hepatocytes in rats
19. Cell cycle models for molecular biology and molecular oncology: Exploring new dimensions
20. Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max
21. Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): Comparison with other delivery routes
22. Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals
23. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration
24. Perspectives in antisense therapeutics
25. Antitumor activity and pharmacokinetics of a mixed backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration
26. A specificity comparison of four antisense types: Morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA